brand:
JAYDESS®
origin:
EU
manufacturer:
Bayer
active substances:
LEVONORGESTREL
strength:
13.5mg per IUS
pack size:
1 IUD
JAYDESS® is a small T-shaped intrauterine system (IUS) designed for contraception. It contains 13.5 mg of levonorgestrel, a hormone used in various contraceptive pills. The device is placed inside the uterus (womb) where it slowly releases the hormone over a period of 3 years, preventing pregnancy through several mechanisms. This product provides a long-term, reversible contraception option.
JAYDESS® is used for the prevention of pregnancy and is suitable for women who desire a long-term, but reversible, method of contraception. It does not act as an emergency contraceptive and should not be used after unprotected intercourse as a means of immediate contraception.
JAYDESS® prevents pregnancy in several ways:
JAYDESS® contains 13.5 mg of levonorgestrel, which is released at an initial rate of 14 mcg/day. This release rate decreases over time, reducing to about 5 mcg/day by the end of the third year.
After 3 years, JAYDESS® must be removed and can be replaced by another device immediately if continued contraception is desired. Removal typically involves a minor procedure, during which the threads of the device are gently pulled.
The most common side effects with JAYDESS® occur within the first 3 to 6 months after insertion and may include changes in menstrual bleeding patterns. Over time, most users experience fewer bleeding days and lighter periods, and some women may stop having periods altogether.
Women with specific health conditions should avoid using JAYDESS®:
Some medications may affect the efficacy of JAYDESS® by influencing the metabolism of levonorgestrel. Women using JAYDESS® should inform their healthcare provider if they are taking or planning to take any of the following medications:
Healthcare providers should consider alternative or additional contraceptive methods for patients using any of the above medications.
In clinical trials, JAYDESS® demonstrated high efficacy in preventing pregnancy, with a failure rate of less than 1% over the 3-year period. Clinical outcomes also showed a significant reduction in menstrual bleeding in many users.
In rare cases where pregnancy occurred while using JAYDESS®, ectopic pregnancy was more likely compared to women who were not using contraception. However, the overall risk remains lower than in women using no contraception at all.
There are some conditions under which JAYDESS® should be used with caution. Women with congenital heart disease, valvular heart disease, or those who are at increased risk of infections should discuss with their healthcare provider whether JAYDESS® is appropriate for them.
JAYDESS® should be stored in a cool, dry place, with a temperature not exceeding 30°C. The system should remain in its original sterile packaging until it is ready for insertion by a healthcare professional. Once inserted, it is recommended to schedule regular check-ups every 4 to 12 weeks and annually after that.